PD-1/PD-L1抑制剂治疗胃癌的研究现状与进展

马 苇萍, 崔 丽荣, 张 翔
青海大学附属医院

摘要


胃癌是世界范围内广泛存在的恶性肿瘤之一，其发病率和死亡率始终处于较高水平，严重威胁着人类身心健康。目前，胃癌的传统治疗手段主要包括化疗、靶向治疗及手术切除等。然而，这些传统治疗方法均存在一定的局限性，整体治疗效果并不理想，患者的预后情况也往往不容乐观。免疫治疗作为一种新兴的治疗手段，特别是针对程序性死亡受体-1（PD-1）和程序性死亡配体1（PD-L1）通路的抑制剂，在胃癌治疗中取得了显著进展，为患者带来了新的生机。本综述旨在总结PD-1/PD-L1抑制剂在胃癌治疗中的作用机制及应用现状，探讨其在胃癌治疗中的潜在获益人群与治疗后的疗效评价，以期为临床治疗提供参考，降低治疗风险，实现个体化治疗，提升患者生存质量，改善患者的总生存期。

关键词


胃癌；PD-1/PD-L1抑制剂；治疗；疗效

全文:

PDF


参考


[1]Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.

[2]Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20(5):338-349.

[3]中华人民共和国国家卫生健康委员会医政医管局.胃癌诊疗指南（2022年版）.中华消化外科杂志，2022，21（9）：1137-1164.

[4]CAO Ni-da, ZHU Xiao-hong, MA Fang-qi, et al. Chinese Medicine Prolongs Overall Survival of Chinese Patients with Advanced Gastric Cancer: Treatment Pattern and Survival Analysis of a 20-Year Real-World Study[J]. Chinese Journal of Integrative Medicine, 2024,30(6):489-498.

[5]Xu AM, Huang L, Liu W, et al. Neoadjuvant chemotherapy followed by surgery versus surgery alone for gastric carcinoma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9(1):e86941.

[6]曹馨，张进萍，涂丽英等.PD-1/PD-L1轴的作用及其在胃肠道肿瘤免疫治疗中的意义[J].生物化学与生物物理进展，2024，51（8）：1834-1847

[7]Gibbons Johnson R M, Dong H. Functional expression of programmed Death-Ligand 1 (B7-H1) by immune cells and tumor cells. Front Immunol, 2017, 8:961

[8]Dong W, Wu X, Ma S, et al. The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector. Cancer Discov, 2019, 9(10): 1422-1437

[9]Shen X, Zhang L, Li J, et al. Recent findings in the regulation of programmed death ligand 1 expression. Front Immunol, 2019, 10:1337

[10]Thakur N, Paik K Y, Hwang G, et al. High expression of PD-L1 is associated with better survival in pancreatic/periampullary cancers and correlates with epithelial to mesenchymal transition. Diagnostics (Basel), 2021, 11(4):597

[11]Boussiotis VA. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med. 2016;375(18):1767-1778.

[12]Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):10. Published 2019 Jan 15.

[13]Makuku R, Khalili N, Razi S, et al. Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy. J Immunol Res. 2021;2021:6661406.

[14]Bevins N J, Okamura R, Montesion M, et al. Tumor infiltrating lymphocyte expression of PD-1 predicts response to anti-PD-1/PD-L1 immunotherapy. J Immunother Precis Oncol, 2022, 5(4): 90-97

[15]Boukouris AE, Theochari M, Stefanou D, et al. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. Crit Rev Oncol Hematol. 2022;173:103663.

[16]Cheng B, Xiao Y, Xue M, et al. Recent advances in the development of PD-L1 modulators: degraders, downregulators, and covalent inhibitors[J]. J Med Chem, 2020, 63(24): 15389-15398.

[17]Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10111):2461-2471.

[18]Boku N, Satoh T, Ryu MH, et al. Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer. 2021;24(4):946-958.

[19]Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial [published correction appears in JAMA Oncol. 2019 Apr 1;5(4):579. doi: 10.1001/jamaoncol.2019.0286.]. JAMA Oncol. 2018;4(5):e180013.

[20]Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27-40.

[21]Leone AG, Mai AS, Fong KY, et al. Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups. ESMO Open. 2024;9(11):103962.

[22]Janjigian YY, Ajani JA, Moehler M, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin Oncol. 2024;42(17):2012-2020.

[23]Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial [published correction appears in Lancet Oncol. 2024 Dec;25(12):e626. doi: 10.1016/S1470-2045(24)00650-8.]. Lancet Oncol. 2023;24(11):1181-1195.

[24]Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402(10418):2197-2208.

[25]Qiu MZ, Oh DY, Kato K, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876. Published 2024 May 28.

[26]Boku N, Ryu MH, Kato K, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30(2):250-258.

[27]Triantafillidis JK, Konstadoulakis MM, Papalois AE. Immunotherapy of gastric cancer: Present status and future perspectives. World J Gastroenterol. 2024;30(8):779-793.

[28]Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571-1580.

[29]Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study [published correction appears in Lancet. 2021 Nov 20;398(10314):1874. doi: 10.1016/S0140-6736(21)02487-9.]. Lancet. 2021;398(10302):759-771.

[30]邓，N.，燕，Z.，王，S.等.在所有联合阳性评分分级下，免疫检查点抑制剂在人表皮生长因子受体2阴性、晚期转移性或不可切除的胃癌中的应用：基于个体患者数据重建和二次分析的疗效评估.临床治疗学，2025，47（2），148-157.

[31]Yoon HH, Jin Z, Kour O, et al. Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials. JAMA Oncol. 2022;8(10):1456-1465.

[32]中国抗癌协会胃癌专业委员会，梁寒，朱正纲等.基于PD-L1蛋白表达水平的胃癌免疫治疗专家共识（2023年版）[J].中国肿瘤临床，2024，51（2）：55-63

[33]Vickram S, Infant SS, Manikandan S, et al. Immune biomarkers and predictive signatures in gastric cancer: Optimizing immunotherapy responses. Pathol Res Pract. 2025;265:155743.

[34]Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.

[35]Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [published correction appears in Lancet Oncol. 2019 May;20(5):e242. doi: 10.1016/S1470-2045(19)30240-2.]. Lancet Oncol. 2017;18(3):e143-e152.

[36]赵静，苏春霞.《CSCO免疫检查点抑制剂相关的毒性管理指南》解读：对比NCCN免疫治疗相关毒性管理指南[J].实用肿瘤杂志，2020，35（01）：11-15.

[37]中国抗癌协会胃癌专业委员会.免疫检查点抑制剂用于进展期胃癌围手术期治疗的中国专家共识（2024版）[J].中华消化外科杂志，2024，23（3）：309-322.


Refbacks

  • 当前没有refback。